Rituximab-CHOP-ESHAP vs CHOP-ESHAP-high-dose therapy vs conventional CHOP chemotherapy in high-intermediate and high-risk aggressive non-Hodgkin's …
T Intragumtornchai, U Bunworasate… - Leukemia & …, 2006 - Taylor & Francis
With currently available combination chemotherapy regimens, the outcome of the patients
newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high'and
'high-intermediate'risk groups according to the international prognostic index (IPI) is still
unsatisfactory and a more innovative therapy is urgently required to improve the survival of
the patients. The purpose of this study was to compare the efficacy of rituximab given in
combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and …
newly diagnosed with aggressive non-Hodgkin's lymphoma (NHL) identified as 'high'and
'high-intermediate'risk groups according to the international prognostic index (IPI) is still
unsatisfactory and a more innovative therapy is urgently required to improve the survival of
the patients. The purpose of this study was to compare the efficacy of rituximab given in
combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) and …
以上显示的是最相近的搜索结果。 查看全部搜索结果